Instrument Inactif

Autres langues Pharmacyclics, Inc.

Actions

US7169331060

Recherche biotechnologique et médicale

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

05/03/15	Wall Street se reprend un peu dans un climat d'attente	RE
05/03/15	DJ Industrial : Wall Street se reprend un peu dans un climat d'attente	RE

Autres langues

07/01/16	Pharmacyclics : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma
07/01/16	Pharmacyclics : AbbVie’s Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers
07/01/16	Pharmacyclics : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent
07/01/16	Pharmacyclics : AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment–Naïve Chronic Lymphocytic Leukemia
07/01/16	Pharmacyclics : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s Macroglobulinemia in Europe
07/01/16	Pharmacyclics : Ibrutinib (IMBRUVICA®) Improved Survival for Treatment–Naïve Chronic Lymphocytic Leukemia Patients in Phase III RESONATETM-2 Trial
07/01/16	Pharmacyclics : Ibrutinib (IMBRUVICA®) Improved Survival for Treatment–Naïve Chronic Lymphocytic Leukemia Patients in Phase III RESONATE-2 Trial
06/05/15	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal
29/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer
21/04/15	Mylan NV : Generic drugmaker Teva makes $40 billion offer for rival Mylan
21/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan offer as soon as this week
21/04/15	Pharmacyclics : Stock Updates on Biotech -- Celgene, Amgen, PDL BioPharma, Amarin, and Pharmacyclics
08/04/15	Actavis : Generic drugmaker Mylan offers $29 billion for Perrigo
01/04/15	Pharmacyclics : Solid Tumor Study Investigating Ibrutinib (IMBRUVICA®) in Combination with Anti-PD-L1 Antibody (MEDI4736) Commences in Patients with Relapsed/Refractory Non-Small Cell Lung, Breast and Pancreatic Cancers
18/03/15	PHARMACYCLICS : SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
10/03/15	Pharmacyclics : Stockholders Encouraged to Contact Securities Law Firm about Takeover
09/03/15	PHARMACYCLICS : SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to AbbVie
09/03/15	Pharmacyclics : INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Pharmacyclics Inc. of Commencement of Class Action Investigation Concerning the Fairness of the Sale of the Company to AbbVie
09/03/15	Pharmacyclics : Ryan & Maniskas, LLP : Announces Investigation of Pharmacyclics Inc.
07/03/15	Pharmacyclics : SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Pharmacyclics, Inc. - PCYC
06/03/15	Pharmacyclics : Harwood Feffer LLP : Announces Investigation of Pharmacyclics, Inc.
05/03/15	AbbVie : CEO defends Pharmacyclics deal to sceptical investors
05/03/15	Wall Street closes up slightly ahead of jobs report
05/03/15	Pharmacyclics : EQUITY ALERT: The Rosen Law Firm Announces Investigation of Pharmacyclics Inc. Concerning its Proposed Sale to AbbVie Inc. – PCYC
05/03/15	Pharmacyclics : SHAREHOLDER ALERT: Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of Investors of Pharmacyclics, Inc. - PCYC